New proposed ballot measure in blue state raises eyebrows over who it's named after: 'Road side lunatics'
A proposed ballot initiative in California is named after alleged UnitedHealthcare CEO assassin Luigi Mangione.
The Luigi Mangione Access to Health Care Act submitted to the California Attorney General's Office would make it illegal for an insurance company to "delay, deny or modify any medical procedure or medication" that is suggested by a licensed physician in the Golden State where there could be serious consequences such as "disability, death, amputation, permanent disfigurement, loss or reduction of any bodily function," the document states. It was filed by Paul Eisner, a longtime Los Angeles-based attorney.
The terms "delay" and "deny" were made popular by the healthcare book "Delay, Deny, Defend: Why Insurance Companies Don't Pay Claims and What You Can Do About." The words "delay, deny, and depose" were reportedly inscribed on the casings of the bullets that killed Brian Thompson on Dec. 4.
"What" Rob Pyers, research director for California Target Book, posted on X.
"A proposed ballot initiative has been filed in California entitled "The Luigi Mangioni (sic) Access to Health Care Act." Actually," Los Angeles-based conservative activist Elizabeth Barcohana said.
"THE LUIGI MANGIONI (sic) ACCESS TO HEALTH CARE ACT" Seriously???? A ballot initiative about health care submitted today to the California Attorney General is named after the accused killer. Crazy," author Gerald Posner wrote.
"I'm starting to suspect the Democrats in charge of California might actually just be simple road side (sic) lunatics after all," Ruthless Podcast Executive Producer Leigh Wolf said on X.
Mangione reportedly faced "chronic back pain," according to Honolulu Civil Beat, and issues after a spinal procedure.
"Pain in general affects our mental well-being, how we go on in our day-to-day life and function. If you're reminded of an injury in your body, and you live in pain, it can be something that really rattles you," board-certified neurosurgeon Dr. Besty Grunch told Fox News Digital in December.
"In this alleged circumstance, you have a 26-year-old, fit guy that has an injury and needs care," she added. "And he may reflect his pain on someone else or blame it on someone else. And [that] can escalate to a point of suicidal or even homicidal thoughts."
Mangione is currently charged with murder by both New York and the federal government, and he has pleaded not guilty.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Julianne Hough documents egg freezing process
Julianne Hough has undergone egg freezing treatment for the third time. The Dancing With the Stars co-presenter - who revealed in 2008 she has endometriosis, a condition where tissue grows outside of the womb lining - thinks it is important to be transparent about her fertility journey in the hope she can help other women. She wrote on Instagram: "I just want to take a moment to say thank you to Dr. Carolyn Alexander and the incredible team at SCRC. Navigating fertility is never simple, especially with endometriosis and my own personal timeline and hopes around having children… but with them, I've always felt safe, supported, and fully informed. "This is my third round of egg freezing and I know it's not always the most comfortable thing to talk about, let alone share publicly. But I've realized how important it is to open up about these things. Women all over the world are quietly walking into doctors' offices, making huge, brave decisions about their bodies and their futures. It's one of the most vulnerable experiences… physically, emotionally, and for sure hormonally. "If sharing just a small piece of my journey helps someone feel less alone, or inspires them to ask questions and explore what's right for them, then I feel like it's worth it. I truly couldn't be more grateful for this team who's been with me since my second endometriosis laparoscopy surgery back in 2017… they've been like family ever since [yellow heart emoji] (sic)" The 36-year-old dancer accompanied the post with a video documenting the process, which included her injecting her stomach to stimulate her folicles to produce more eggs, and also a "trigger shot" to release them. On the sixth day of the process, she said: "Just woke up, hormones are kicking in, my boobs are getting bigger, everything is happening." She also showed her bloated stomach, a side effect from the treatment. She said: "Look. It's like a little pregger belly. Cutie."
Yahoo
3 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indianapolis Star
15 hours ago
- Indianapolis Star
FDA: More cucumbers, ready-to-eat products recalled in growing salmonella outbreak
A Maryland food company has recalled specific salsa and cucumber products because they were made with cucumbers that are possibly contaminated with salmonella. TGD Cuts, LLC of Jessup, Maryland, is recalling some tub and tray products because they contained cucumbers from Boynton Beach, Florida-based Bedner Growers Inc., which have been linked to a salmonella outbreak. TGD Cuts distributed the affected products, which included salsas, sliced cucumbers and cucumber spears, to retail and foodservice locations in Maryland, Virginia, Pennsylvania, New Jersey, and North Carolina, according to the Food and Drug Administration (FDA). The products had use-by dates ranging from May 20 to May 28 and are unlikely to be in stores or being used. No illnesses have been reported in connection with the products, the FDA said. Egg recall: Brown eggs sold at some Walmart stores have salmonella risk The initial May 19 recall involved cucumbers sold directly to consumers at Bednar's Farm Fresh Market, according to notices published May 19 by the Centers for Disease Control and Prevention (CDC) and the FDA. Subsequent recalls have been announced by grocers such as Harris Teeter, Kroger and Walmart for repackaged cucumbers for resale under different brand names or those used in ready-to-eat products, including vegetable trays and salads. The cucumbers, distributed by Fresh Start Produce Sales of Delray, Florida, also led to Target recalling individual cucumbers on May 30, specifically cucumber two-packs and various prepared foods products. In addition to the growing cucumber-related recall, other products have been recalled recently for potential salmonella contamination. The FDA on May 28 upgraded a recall of tomatoes distributed in three southern states to a Class I recall, meaning consumption of the food could cause serious health complications or lead to death. Then, on June 6, the CDC and FDA linked brown eggs sold in nine states – including at some Walmart stores – to an ongoing Salmonella Enteritidis outbreak, in which 79 people have been sickened and at least 21 hospitalized. Customers who purchased any products from TGD Cuts should get rid of them or return them for a full refund. Here is the list of products recalled due to a possible salmonella risk. Salmonella poisoning causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms, which include diarrhea, fever and stomach cramps, will usually occur six hours to six days after exposure and may last up to seven days. Symptoms from severe infections may include aches, headaches, elevated fever, lethargy, rashes, and blood in urine or stool. Mike Snider is a reporter on USA TODAY's Trending team. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @ & @mikesnider & msnider@
